Ascendia

  MARKET NEWS

Ocugen Announces Positive Preliminary Safety & Efficacy Results From Phase 1/2 Trial of Modifier Gene Therapy Product Candidate
Microcarrier Market is Expected to Reach $2.9 Billion 
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
Ocean Biomedical Announces Notice of Allowance for Patent Application for Developing “Whole New Class” of Malaria Therapeutics
Dyadic Announces Expanded Licensing Agreement to Develop & Commercialize Vaccines & Biologics for African Continent
Immuneering Announces Positive Initial Phase 1 Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

  FEATURED EDITORIAL

  COMPANY PROFILE

Singota Solutions is a contract development and manufacturing organization (CDMO) focused on getting products to patients faster by being agile, accountable, and transparent. Founded in 2006, and headquartered in Bloomington, Indiana, Singota provides responsive, quality driven outsourcing services. Singota fills parenterals into ready-to-use vials, syringes, or cartridges utilizing our gloveless, robotic, SA25 aseptic filling workcell for pre-clinical, clinical, and small commercial therapies. Our manufacturing process ensures freedom from in-process human intervention by not only removing the impact of operators from the initial aseptic environment but also by removing operator variability from the filling process. Click here for more.

  EXCLUSIVE ONLINE CONTENT

ProBioGen & ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients

ProBioGen & ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients

ProBioGen and ImmunOs Therapeutics recently announcd the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs’ lead program for the….

Kala Pharmaceuticals Receives FDA Fast Track Designation for Human MSC-S Therapy for Persistent Corneal Epithelial Defect

Kala Pharmaceuticals Receives FDA Fast Track Designation for Human MSC-S Therapy for Persistent Corneal Epithelial Defect

Kala Pharmaceuticals, Inc. recently announced the US FDA has granted Fast Track designation for Kala’s human mesenchymal stem cell secretome (MSC-S) therapy (KPI-012) for the treatment of….

Biogen Exercises Option With Denali to Develop & Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

Biogen Exercises Option With Denali to Develop & Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

Biogen Inc. and Denali Therapeutics Inc. recently announced Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV):Amyloid beta program (ATV:Aβ). Accumulation of Aβ plaque in….

Meridian Medical Technologies Investing 0+ Million in Bridgeton, MO, Expansion

Meridian Medical Technologies Investing $100+ Million in Bridgeton, MO, Expansion

Meridian Medical Technologies recently announced during National Community Development Week it will expand manufacturing capabilities in….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

The manufacture of ophthalmic ointments is much more complex than the production of ocular liquid therapies and presents several unique challenges. It is essential for drug developers to choose outsourcing partners with extensive manufacturing experience with these specialized capabilities in …

WHITEPAPER - Improve Process Economics & Enable High Protein Concentrations

WHITEPAPER - Improve Process Economics & Enable High Protein Concentrations

This white paper evaluates the effect of the excipients in the Viscosity Reduction Platform on ultrafiltration processes used to produce a highly concentrated formulation of a monoclonal antibody (mAb). Two filtration methods are demonstrated in this work.

Click here to …

WHITEPAPER - Purity is Paramount: Assessing N-Oxide Impurities in Lipids Used in Lipid Nanoparticle Delivery Systems

WHITEPAPER - Purity is Paramount: Assessing N-Oxide Impurities in Lipids Used in Lipid Nanoparticle Delivery Systems

By: Sabrina Metze, PhD, Ulrich Klöckner, PhD, Lars Geiger, PhD, Justin Schieven, PhD, and Thomas Böhmer*

Summary

The quality of lipids in a lipid nanoparticle assembly is critically important to the functionality of mRNA-based therapeutics. Packer et al. have identified …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 26 – Particle Design Technology
May 3 – Nasal Delivery